The 2026 Guideline Update on Statin Deprescribing Is Here

https://youtu.be/cYcRCtllWm8

Just posted this video on Red Eye in Primary Care- you can check it out here!

-Simon

We often treat statins like essential nutrients, but for our oldest patients, the risk-benefit balance shifts dramatically as they age.

A recent clinical practice guideline from Deprescribing.org (in press - soon to be released in the CFP journal) - provides a new framework to help you navigate when to continue or discontinue therapy in adults aged 65 and older.

This shift moves us away from the default of "keep them on it forever" and toward a more thoughtful, patient-centred evaluation. If your patient is at end-of-life, the evidence now supports a more relaxed approach. This isn't just theory, it's an actionable change you can bring to your clinic tomorrow.

We use the Stop-Stat Assessment to guide these conversations. Instead of viewing statins as an immutable prescription, we must categorize patients based on their current clinical trajectory.

The Stop-Stat Assessment factors to review:

• Life expectancy (is it less than 12 months?)

• Level of frailty, mobility, and complexity

• Cognitive status

• Pill burden

• Patient values and healthcare goals

  
  

What about the patients who are not at end-of-life? The guideline suggests continuing statins for primary or secondary prevention in older adults who are not near the end of their lives. This remains a conditional recommendation based on low-certainty evidence, meaning you have license to exercise clinical judgment based on the patient's individual goals.

For those facing life-limiting illness, the landscape changes. The panel suggests deprescribing statins in these patients in whom:

💡 Burden of medication > Cardiovascular benefit

When you have this conversation, frame it around the patient's comfort and their personal priorities rather than just their lipid panel.

Exam Tip: When you are studying for the MCQ-SAMPs, watch out for "statin intolerance" distractors versus true "end-of-life deprescribing" scenarios. Can you distinguish between a patient who just needs a dose adjustment and a patient who is physically frail with a limited life expectancy? Don't assume the answer is always "keep the statin." Consider the frailty and the prognosis first. And on the SOO if you can name "the new Deprescribing.org guideline" you will look super sharp!

What do attendees say about The Review Course?

"Concise, important updates on priority topics/common issues in family practice" - The Review Course Attendee Register here!

Source